Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally | The Motley Fool
This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.

Source: The Motley Fool
This RNA therapeutics innovator for rare diseases reported a notable insider sale amid a year of dramatic share price gains.